Published in Biochemistry on November 02, 1999
Structural basis for the conformational adaptability of apolipophorin III, a helix-bundle exchangeable apolipoprotein. Proc Natl Acad Sci U S A (2002) 1.25
Apolipoprotein c1 association with hepatitis C virus. J Virol (2008) 1.24
Amyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights. Adv Exp Med Biol (2015) 0.98
Amphipathic α-helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles. PLoS Pathog (2014) 0.93
Role of secondary structure in protein-phospholipid surface interactions: reconstitution and denaturation of apolipoprotein C-I:DMPC complexes. Biochemistry (2007) 0.87
Apolipoprotein C-I binds more strongly to phospholipid/triolein/water than triolein/water interfaces: a possible model for inhibiting cholesterol ester transfer protein activity and triacylglycerol-rich lipoprotein uptake. Biochemistry (2012) 0.85
Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N- and C-terminal helix. J Lipid Res (2010) 0.84
Several Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released Viruses. PLoS One (2015) 0.83
Aromatic residues in the C-terminal helix of human apoC-I mediate phospholipid interactions and particle morphology. J Lipid Res (2008) 0.80
Micelle-induced folding of spinach thylakoid soluble phosphoprotein of 9 kDa and its functional implications. Biochemistry (2006) 0.80
Helical domains that mediate lipid solubilization and ABCA1-specific cholesterol efflux in apolipoproteins C-I and A-II. J Lipid Res (2013) 0.79
Changes in helical content or net charge of apolipoprotein C-I alter its affinity for lipid/water interfaces. J Lipid Res (2013) 0.78
Structural studies of a baboon (Papio sp.) plasma protein inhibitor of cholesteryl ester transferase. Protein Sci (2000) 0.75
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86
Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J (1986) 4.32
Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res (1984) 4.12
Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem (1978) 3.57
Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science (1991) 3.42
Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem (1987) 3.04
Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem (1981) 3.02
Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature (1982) 3.01
Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science (1994) 2.98
Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. J Biol Chem (1977) 2.86
Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci U S A (1986) 2.80
A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest (1989) 2.71
Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem (1982) 2.71
Human apolipoprotein E. The complete amino acid sequence. J Biol Chem (1982) 2.64
Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem (1990) 2.42
A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest (1980) 2.27
Two independent lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo-B,E and apo-E receptors. J Clin Invest (1981) 2.27
Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A (1995) 2.11
Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem (1996) 2.06
Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem (1994) 2.04
Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry (2000) 2.01
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res (1982) 2.01
Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci U S A (1982) 1.96
Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A (1994) 1.94
Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A (1987) 1.93
Canine lipoproteins and atherosclerosis. II. Characterization of the plasma lipoproteins associated with atherogenic and nonatherogenic hyperlipidemia. Circ Res (1974) 1.91
Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res (1990) 1.90
Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100. Nature (1986) 1.85
Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol (1994) 1.84
Subfractionation of human high density lipoproteins by heparin-Sepharose affinity chromatography. J Lipid Res (1980) 1.84
The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. J Biol Chem (1983) 1.75
Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A (1994) 1.74
Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem (1988) 1.72
The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J Biol Chem (1983) 1.67
Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry (1975) 1.66
Apoprotein (E--A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. J Biol Chem (1978) 1.60
Canine hyperlipoproteinemia and atherosclerosis. Accumulation of lipid by aortic medial cells in vivo and in vitro. Am J Pathol (1977) 1.60
Inhibition of receptor-mediated clearance of lysine and arginine-modified lipoproteins from the plasma of rats and monkeys. Proc Natl Acad Sci U S A (1980) 1.59
Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem (1988) 1.57
Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 1.54
Apoprotein (E--A-II) complex of human plasma lipoproteins. II. Receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E--A-II) complex. J Biol Chem (1978) 1.52
Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. Proc Natl Acad Sci U S A (2001) 1.51
Swine lipoproteins and atherosclerosis. Changes in the plasma lipoproteins and apoproteins induced by cholesterol feeding. Biochemistry (1975) 1.50
Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem (1986) 1.50
Accelerated clearance of low-density and high-density lipoproteins and retarded clearance of E apoprotein-containing lipoproteins from the plasma of rats after modification of lysine residues. Proc Natl Acad Sci U S A (1979) 1.48
Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100. Lancet (1992) 1.46
Canine lipoproteins and atherosclerosis. I. Isolation and characterization of plasma lipoproteins from control dogs. Circ Res (1974) 1.44
Isolation and characterization of apolipoprotein E. Methods Enzymol (1986) 1.39
Molecular cloning and expression of partial cDNAs and deduced amino acid sequence of a carboxyl-terminal fragment of human apolipoprotein B-100. Proc Natl Acad Sci U S A (1985) 1.35
Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II. Proc Natl Acad Sci U S A (1977) 1.35
Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. J Clin Invest (1989) 1.35
Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem (1994) 1.34
Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J Biol Chem (1993) 1.33
Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. Biochim Biophys Acta (1979) 1.33
Human apolipoprotein B-100 heparin-binding sites. J Biol Chem (1987) 1.32
A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells. Gene Ther (1996) 1.31
Lipid binding-induced conformational change in human apolipoprotein E. Evidence for two lipid-bound states on spherical particles. J Biol Chem (2001) 1.31
Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J Biol Chem (1988) 1.31
Dissociation of the stimulatory activities of staphylococcal enterotoxins for T cells and monocytes. J Exp Med (1990) 1.29
Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E. Proc Natl Acad Sci U S A (1985) 1.25
Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J Lipid Res (1992) 1.25
The rat arginine-rich apoprotein and its redistribution following injection of iodinated lipoproteins into normal and hypercholesterolemic rats. Atherosclerosis (1977) 1.24
Stereochemistry of methyl group insertion in corrinoid biosynthesis. Determination of carbon isotope chirality by 13C nuclear magnetic resonance. J Am Chem Soc (1973) 1.23
Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. J Biol Chem (1983) 1.23
Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J Neuropathol Exp Neurol (1994) 1.22
Interaction of the N-terminal domain of apolipoprotein E4 with heparin. Biochemistry (2001) 1.21
Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. Biochem Biophys Res Commun (1986) 1.20
Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant. J Clin Invest (1989) 1.20
Conformations of human apolipoprotein E(263-286) and E(267-289) in aqueous solutions of sodium dodecyl sulfate by CD and 1H NMR. Biochemistry (1996) 1.19
Apolipoprotein-mediated plasma membrane microsolubilization. Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. J Biol Chem (1999) 1.19
A convenient synthesis of phosphatidylcholines: acylation of sn-glycero-3-phosphocholine with fatty acid anhydride and 4-pyrrolidinopyridine. J Lipid Res (1979) 1.17
New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E. J Biol Chem (2001) 1.17
Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. J Clin Invest (1983) 1.15
Measurement and prediction of the rates of spontaneous transfer of phospholipids between plasma lipoproteins. Biochim Biophys Acta (1984) 1.15
Functional characterization of apolipoprotein E isoforms overexpressed in Escherichia coli. Protein Expr Purif (1999) 1.14
Tissue expression studies on the mouse acyl-CoA: cholesterol acyltransferase gene (Acact): findings supporting the existence of multiple cholesterol esterification enzymes in mice. J Lipid Res (1997) 1.12
Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein [a] and that cause lipid accumulation in macrophages. J Clin Invest (1986) 1.12
An improved polystyrene support for solid phase peptide synthesis. J Org Chem (1976) 1.11
In the absence of a downstream element, the apolipoprotein E gene is expressed at high levels in kidneys of transgenic mice. J Biol Chem (1990) 1.10
Apolipoprotein E;-low density lipoprotein receptor interaction. Influences of basic residue and amphipathic alpha-helix organization in the ligand. J Lipid Res (2000) 1.09
Conformational reorganization of the four-helix bundle of human apolipoprotein E in binding to phospholipid. J Biol Chem (2000) 1.09
Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. J Biol Chem (1984) 1.08
Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J (2006) 1.08
Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol (1996) 1.07
Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope. J Biol Chem (1987) 1.07
Expression of apolipoprotein E by cultured vascular smooth muscle cells is controlled by growth state. J Cell Biol (1988) 1.07
Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia. J Clin Invest (1983) 1.07
Atherogenic hyperlipoproteinemia induced by cholesterol feeding the Patas monkey. Biochemistry (1976) 1.05
A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest (1980) 1.05
The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J Biol Chem (1992) 1.04
Biosynthesis of prodigiosin. Incorporation patterns of C-labeled alanine, proline, glycine, and serine elucidated by fourier transform nuclear magnetic resonance. J Am Chem Soc (1973) 1.04
Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia. Proc Natl Acad Sci U S A (1984) 1.03
Recognition of mos-related proteins with an antiserum to a peptide of the v-mos gene product. J Gen Virol (1985) 1.03
Apolipoprotein E immunoreactive deposits in inclusion-body muscle diseases. Lancet (1994) 1.02
Epitopes associated with a synthetic hepatitis B surface antigen peptide. J Immunol (1983) 1.02
Isolation and characterization of an apoprotein from the d less than 1.006 lipoproteins of human and canine lymph homologous with the rat A-IV apoprotein. Biochem Biophys Res Commun (1978) 1.01
Effect of arginine 172 on the binding of apolipoprotein E to the low density lipoprotein receptor. J Biol Chem (2000) 1.01